Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023–January 2024

• Authors: ANTUNES Liliana; MAZAGATOS Clara; MARTÍNEZ-BAZ Iván; NAESENS Reinout; BORG Maria-Luise; PETROVIC Goranka; FATUKASI Terra; JANCORIENE Ligita; MACHADO Ausenda; OROSZI Beatrix; HUSA Petr; LAZAR Mihaela; DÜRRWALD Ralf; HOWARD Jennifer; MELO Aryse; PÉREZ-GIMENO Gloria; CASTILLA Jesús; BERNAERT Eva; DŽIUGYTÉ Aušra; LOVRIC MAKARIC Zvjezdana; FITZGERALD Margaret; MICKIENÉ Auksé; GOMEZ Veronica; TÚRI Gergö; SOUČKOVÁ Lenka; MARIN Alexandru; TOLKSDORF Kristin; NICOLAY Nathalie; ROSE Angela MC
• Year of publication: 2024
• Type: Article in Periodical
• Magazine / Source: Influenza and Other Respiratory Viruses
• MU Faculty or unit: Faculty of Medicine
• Web: https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.13360?src=getftr
• Doi: http://dx.doi.org/10.1111./irv.13360
• Keywords: COVID-19 XBB1.5 vaccine; Europe; SARS-CoV- 2 hospitalisation; vaccine effectiveness
• Description: We conducted a multicentre test-negative case–control study covering the period from October 2023 to January 2024 amongadult patients aged ? 18 years hospitalised with severe acute respiratory infection in Europe. We provide early estimates of theeffectiveness of the newly adapted XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS- CoV-2 hospitalisation. Vaccineeffectiveness was 49% overall, ranging between 69% at 14–29 days and 40% at 60–105 days post vaccination. The adapted XBB.1.5COVID-19 vaccines conferred protection against COVID-19 hospitalisation in the first 3.5 months post vaccination, withVE > 70% in older adults (? 65 years) up to 1 month post vaccination.